1 **Title Page**
2
3 **Article Type:** Research Article
4
5 **Title:** Potential impact of outpatient stewardship interventions on antibiotic exposures of
6 bacterial pathogens
7

8 **Authors:** Christine Tedijanto,[1] Yonatan H Grad,[2,3] Marc Lipsitch[1,2]
9
10 **Author Affiliations:** [1] Center for Communicable Disease Dynamics, Department of
11 Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;
12 [2] Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
13 Health, Boston, Massachusetts, USA; [3] Division of Infectious Diseases, Brigham and Women's
14 Hospital, Harvard Medical School, Boston, Massachusetts, USA
15
16 **Corresponding Author:** Christine Tedijanto, ctedijanto@g.harvard.edu

17
18 **Manuscript Word Count:** 3,025
19

Abstract

The relationship between antibiotic stewardship and population levels of antibiotic resistance remains unclear. In order to better understand shifts in selective pressure due to stewardship, we use publicly available data to estimate the effect of changes in prescribing on exposures to frequently used antibiotics experienced by potentially pathogenic bacteria that are asymptomatically colonizing the microbiome. We quantify this impact under four hypothetical stewardship strategies. In one scenario, we estimate that elimination of all unnecessary outpatient antibiotic use could avert 6 to 48% (IQR: 17 to 31%) of exposures across pairwise combinations of sixteen common antibiotics and nine bacterial pathogens. All scenarios demonstrate that stewardship interventions, facilitated by changes in clinician behavior and improved diagnostics, have the opportunity to broadly reduce antibiotic exposures across a range of potential pathogens. Concurrent approaches, such as vaccines aiming to reduce infection incidence, are needed to further decrease exposures occurring in "necessary" contexts.

Introduction

Antibiotic consumption is a known driver of antibiotic resistance. In developed nations, over 80% of antibiotic consumption for human health occurs in the outpatient setting (European Centre for Disease Prevention and Control, 2018; Public Health Agency of Canada, 2018; Public Health England, 2017; Swedres-Svarm, 2017), and US-based studies conducted across different subpopulations have estimated that 23-40% of outpatient prescriptions may be inappropriate (Chua, Fischer, & Linder, 2019; Fleming-Dutra et al., 2016; Olesen, Barnett, MacFadden, Lipsitch, & Grad, 2018). Inappropriate antibiotic use leads to increased risk of adverse events (Linder, 2008; Shehab, Patel, Srinivasan, & Budnitz, 2008), disruption of colonization resistance and other benefits of the microbial flora (Buffie & Pamer, 2013; Khosravi & Mazmanian, 2013), and bystander selection for antibiotic resistance, with little to no health gains for the patient. Recent work on bystander selection estimates that, for 8 of 9 potential pathogens of interest, over 80% of their exposures to commonly used antibiotic classes in the outpatient setting occur when the organisms are asymptomatically colonizing the microbiome, not causing disease (Tedijanto, Olesen, Grad, & Lipsitch, 2018). A corollary of extensive bystander selection is that reductions in use will prevent antibiotic exposures for species throughout the microbiome.

We use publicly available data to quantify potentially avertable exposures of bacterial species to commonly used antibiotics under hypothetical changes in prescribing practice. The set of scenarios included here are intended as thought experiments to explore the upper bounds of avertable antibiotic exposures. Reductions in antibiotic consumption have historically had variable impacts on resistance levels, likely dependent on setting, baseline consumption and resistance patterns, and fitness costs (Andersson & Hughes, 2010; Lipsitch, 2001). In addition,

treatment strategies are primarily guided by randomized controlled trials assessing immediate

clinical outcomes, with less careful consideration given to the microbiome-wide effect of such

decisions. We apply analytical methods to parse out species-level effects of changes in

prescribing practice in order to better understand the potential impact of antibiotic stewardship.

Methods

Scenarios of interest

This analysis includes sixteen antibiotics that are frequently prescribed in the outpatient setting

and nine potentially pathogenic bacterial species that are commonly carried in the normal human

microbiome. For each antibiotic-species pair, we estimate the proportion of antibiotic exposures

experienced by that species that could be averted under four hypothetical scenarios. The

scenarios range from broad elimination of unnecessary prescribing to focused modifications of

antibiotic use for specific indications as follows:

1) Eliminate unnecessary antibiotic use across all outpatient conditions.

2) Eliminate all antibiotic use for outpatient respiratory conditions for which antibiotics are

not indicated.

3) Eliminate all antibiotic use for acute sinusitis.

4) Prescribe nitrofurantoin for all cases of cystitis in women.

Based on previously published work, we consider viral upper respiratory tract infection,

influenza, non-suppurative otitis media, viral pneumonia, bronchitis, and allergy and asthma to

be outpatient respiratory conditions for which antibiotics are not indicated (Fleming-Dutra et al.,

2016). Due to the self-limiting nature and infrequent bacterial etiology of acute sinusitis, there is

weak evidence to support antibiotic treatment (Burgstaller, Steurer, Holzmann, Geiges, & Soyka,

2016; Rosenfeld et al., 2015). However, antibiotics continue to be prescribed at over 80% of US

outpatient visits with a primary diagnosis of acute sinusitis (Smith et al., 2013). In contrast,

antibiotics are always recommended for urinary tract infections (UTIs). Despite being

recommended as a second-line therapy for cystitis due to concerns about resistance,

fluoroquinolones are the most common treatment, prescribed at 40% of outpatient visits for

uncomplicated UTI (Kabbani et al., 2018). We explore the hypothetical scenario of treating all

cases of cystitis in women with nitrofurantoin, a recommended first-line therapy with good

potency against common uropathogens, low levels of resistance, and decreased risk of collateral

damage to the intestinal microbiome due to its propensity to concentrate in the bladder (Gupta et

al., 2011; Gupta, Scholes, & Stamm, 1999; Stewardson et al., 2015).

Data sources and methodology

Extending our recent work on bystander selection (Tedijanto et al., 2018), we used the 2015

National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care

Survey (NAMCS/NHAMCS), the Human Microbiome Project (HMP) (Huttenhower et al., 2012;

The Human Microbiome Project Consortium, 2012), and assorted carriage and etiology studies

to estimate national outpatient antibiotic exposures by drug, species, and condition.

NAMCS/NHAMCS are annual cross-sectional surveys designed to sample outpatient visits in

the United States, and up to five diagnoses and thirty medications may be associated with each

visit. We used methodology developed by Fleming-Dutra and colleagues (Fleming-Dutra et al.,

2016), and applied in other studies (Olesen et al., 2018), to group diagnosis codes into conditions

and link antibiotic prescriptions with the most likely indication. For this analysis, visits with a

diagnosis of acute cystitis (ICD-9-CM: 595.0), unspecified cystitis (595.9) or unspecified UTI

(599.0), without a concurrent diagnosis of pyelonephritis (590.1, 590.8), renal abscess (590.2), or

kidney infection (590.9), were considered to be associated with cystitis. In this analysis, we

maintain the assumption that one antibiotic prescription is equivalent to one exposure; antibiotic

exposures experienced by a given species and associated with a given condition are roughly

estimated as the product of antibiotic prescriptions for that condition and species carriage

prevalence, which is dependent on disease etiology (target exposures) and asymptomatic carriage

prevalence (bystander exposures) (details in Appendix Table 1). For diagnoses where etiology

was not readily available, we assumed that none of our species of interest were causative agents.

These assumptions have been enumerated in detail in prior work (Tedijanto et al., 2018).

We applied proportions of unnecessary antibiotic prescribing by condition and age group

estimated by Fleming-Dutra and colleagues based on expert opinion, clinical guidelines, and

regional variability in use (Fleming-Dutra et al., 2016). Since these estimates were reported for

oral antibiotic use in the outpatient setting, we excluded antibiotics that are typically

administered topically or parenterally. For relevant scenarios (1 and 2), we applied the

proportions of unnecessary use evenly across all antibiotic prescriptions.

The proportion of avertable antibiotic exposures for each species is defined by Equation 1. The

equation adopts previously described notation (Tedijanto et al., 2018) with modifications. A

listing of all variables and descriptions can be found in Appendix Table 1. Let a represent

antibiotic, s represent species, i represent ICD-9-CM diagnosis code, and g represent age group.

Prescriptions with $i=0$ were not associated with any ICD-9-CM diagnosis codes, and throughout

the analysis we have weighted outpatient visits to be nationally representative. Let X_{as} be the

number of avertable exposures by antibiotic and species, T_{as} be the total number of exposures by

antibiotic and species, d_{aig} be the number of prescriptions of antibiotic a associated with

diagnosis code i in age group g, p_{sig} be the carriage prevalence of species s among those with

diagnosis code i in age group g, and q_{aig} be the proportion of avertable exposures by diagnosis

code and age group in the given scenario. For example, in the scenario assessing elimination of

all unnecessary antibiotic use, q_{aig} is the proportion of avertable antibiotic use by diagnosis and

age group (Fleming-Dutra et al., 2016). Alternatively, in the scenario assessing elimination of

non-nitrofurantoin treatment for cystitis, q_{aig} is 1 when a is not nitrofurantoin and i is a diagnosis

code associated with cystitis, and 0 elsewhere. Carriage prevalences (p_{sig}) are assumed to be

constant within three age groups (under 1 year, 1-5 years, over 5 years old) (Tedijanto et al.,

2018), while proportions of avertable antibiotic use (q_{aig}) were reported for three different age

groups (0-19 years, 20-64 years, 65 years old and over) (Fleming-Dutra et al., 2016). G is the

smallest set of age groups that accounts for this granularity (under 1 year, 1-5 years, 6-19 years,

20-64 years, 65 years old and over).

Equation 1. Proportion of avertable exposures by species and antibiotic.

$$\frac{X_{as}}{T_{as}} = \frac{\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig} \times q_{aig}}{\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig}}$$

In scenarios where unnecessary use is eliminated (1 and 2), we assume that only bystander

exposures are affected. Equivalently, this presumes that perfect discrimination between bacterial

and non-bacterial etiologies is possible. This results in a slight modification to Equation 1 -- p_{sig}

is changed to p_{s0g} as all eliminated exposures would have occurred during asymptomatic

carriage. For cases where e_{sig} is 1, we assume zero avertable exposures. In addition, we make

slight modifications to q_{aig} when we estimate the proportion of bacterial cases to be larger than

the proportion of necessary prescriptions (Appendix Table 2). As a sensitivity analysis, we

include the proportion of avertable exposures for each species-antibiotic pair under Scenario 1 if

antibiotic use was eliminated equally across both target and bystander exposures (Appendix

Figure 1). All analysis was conducted in R version 3.5.1.

Results

Results for all four scenarios are depicted in Figure 1. We estimate that elimination of

unnecessary antibiotic prescriptions across all outpatient conditions would prevent 6 to 48%

(IQR: 17 to 31%) of antibiotic-species exposures (Figure 1A). The smallest reduction is

associated with *S. pyogenes* exposures to cefdinir and the largest with *H. influenzae* and *E. coli*

exposures to azithromycin. If all unnecessary antibiotic use could be prevented, over 30% of

exposures to amoxicillin-clavulanate, penicillin, azithromycin, clarithromycin, levofloxacin, and

doxycycline across most potential pathogens of interest could be averted. As expected, the

proportion of avertable exposures when all unnecessary outpatient use is eliminated is positively

correlated with previously reported estimates of bystander selection (Appendix Figure 2)

(Tedijanto et al., 2018).

Across all scenarios, the proportion of avertable exposures appears to be primarily driven by the

drug considered. For example, in both scenarios assessing broad elimination of unnecessary

antibiotic use, every species can expect azithromycin exposures to decrease to the greatest extent

as it is the most commonly used antibiotic for respiratory conditions for which antibiotics are not

indicated (Figure 1B). The estimated reductions in azithromycin across species range from 37 to

48% when all outpatient conditions are considered and from 24 to 32% when limited to the

subset of respiratory conditions for which antibiotics are not indicated. High estimates of

avertable exposures for a particular antibiotic reflect both frequent use for the impacted

syndrome(s) and concentrated use for those conditions relative to other indications. Consider the

indication-specific scenarios: ciprofloxacin and sulfamethoxazole-trimethoprim are the most

frequently prescribed antibiotics for cystitis other than nitrofurantoin and have relatively large

estimates of avertable exposures (23 to 44% and 7 to 26%, respectively). While clarithromycin is

only the eighth-most-prescribed antibiotic for acute sinusitis among the included antibiotics, its

concentrated use for acute sinusitis compared to other indications results in relatively large

expected reductions in exposure (up to 9% for *P. aeruginosa* and *S. pyogenes*) compared to other

drugs.

181
182 **Figure 1.** Heatmaps showing the estimated percentage of species exposures to each antibiotic or
183 antibiotic class that could be averted if *A:* unnecessary antibiotic prescriptions across all
184 outpatient conditions, *B:* all antibiotic use for outpatient respiratory conditions for which
185 antibiotics are not indicated, *C:* all antibiotic use for acute sinusitis, or *D:* non-nitrofurantoin

treatment of cystitis in women was eliminated. Drug class results include prescriptions of all
antibiotics in that class, as identified by the Multum Lexicon classification system.
Abbreviations: *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,
AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,
CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,
TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin;
Organisms (x-axis): EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*,
SA=*S. aureus*, SAg=*S. agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years

Characteristics of the bacterial organism of interest also influence the extent of avertable

exposures. Species that are common causes of the affected condition(s) naturally have larger

predicted reductions in exposure. For example, an estimated 33%, 36%, and 44% of

ciprofloxacin exposures to *E. coli*, *K. pneumoniae*, and *P. aeruginosa*, respectively, could be

averted under the cystitis scenario, compared to 23 to 27% across all other organisms. Although

E. coli is the most common cause of UTIs, its estimated exposure reduction in this scenario is

lower than that of *P. aeruginosa*, likely due to the larger number of bystander exposures incurred

by *E. coli* during asymptomatic carriage. Infrequent carriage prevalence in the normal

microbiome is also generally associated with lower proportions of avertable exposures across all

antibiotics (e.g. *S. pyogenes, S. agalactiae*, *M. catarrhalis*).

Discussion

We quantify the species-level impact of changes in antibiotic consumption as the proportion of

antibiotic exposures experienced by common bacterial pathogens that could be averted under

four hypothetical scenarios. In the scenario where unnecessary antibiotic use for all outpatient

conditions is eliminated, we find that up to 48% of exposures (of *H. influenzae* and *E. coli* to

azithromycin) could be avoided. In addition, impact of the intervention across antibiotics and

species is widespread, with half of antibiotic-species pairs expected to experience a reduction in

exposures of over one fifth (22%). For conditions which require antibiotic treatment, such as

UTIs, switching to antibiotics with decreased collateral damage to the microbiome, such as

nitrofurantoin, may be an effective strategy for reducing antibiotic exposures across species.

In three out of four situations we assess, antibiotics are considered entirely unnecessary for some

or all cases. This is a strong assumption in the case of acute sinusitis, as a small number of cases

are truly bacterial and antibiotics are indicated for patients with persistent, severe or worsening

symptoms (Rosenfeld et al., 2015). These scenarios are explored in sensitivity analyses

(Appendix Figure 3). In the future, this method may also be extended to measure net changes in

exposures resulting from more nuanced scenarios where one antibiotic is substituted for another.

We did not assess such changes for nitrofurantoin, as its effects on the microbiome outside of the

bladder are thought to be minimal (Stewardson et al., 2015). The reductions in use presented here

may be practically infeasible due to challenges including similar clinical presentation of viral and

bacterial infections, individual considerations such as allergies (Sakoulas, Geriak, & Nizet, 2018)

or heightened risk of adverse events, misdiagnosis (Filice et al., 2015; Tomas, Getman, Donskey,

& Hecker, 2015), and patient-driven demand (Vanden Eng et al., 2003). Even if elimination of

unnecessary use were fully realized, our results imply that the majority of species' antibiotic

exposures occur in the context of "necessary" antibiotic use. These findings underscore the

importance of considering bystander effects and the need for a multi-pronged approach to

programs aimed at controlling antibiotic resistance. Rapid diagnostics, diagnostics that

accurately discriminate between bacterial and non-bacterial causes, patient education, and

improved decision-making tools and other interventions to motivate changes in clinician

behavior can enhance responsible antibiotic consumption; these should be implemented

simultaneously with prevention measures such as infection control, access to clean water and

sanitation, safe sex interventions, and vaccination, which aim to reduce infection incidence and

thus any antibiotic use.

At the time of this analysis, NHAMCS data from hospital outpatient departments was not yet

available for years after 2011. In the 2010-2011 NAMCS/NHAMCS data, visits to hospital

outpatient departments accounted for 36% of included sampled visits, but just 9% of all

antibiotic mentions. The proportions of avertable exposures including and excluding these visits

for 2010-2011 were similar (Appendix Figure 4); thus, we assumed that antibiotic use and

diagnoses in the existing 2015 data without hospital outpatient department visits was

representative. Additional limitations of the included datasets and method for estimating

antibiotic exposures have been previously enumerated (Tedijanto et al., 2018). Notably, the

NAMCS/NHAMCS does not provide information to link medications with diagnoses, so we

adopted a published tiered system to pair antibiotic use at each visit with the most likely

indication (Fleming-Dutra et al., 2016). For visits with multiple diagnoses, all antibiotic use was

attributed to the single most-likely indication. This method tends to overestimate antibiotic use

for conditions for which antibiotics are almost always indicated, which may lead to clinically

unusual diagnosis-treatment linkages. In the same way, antibiotic prescriptions are

underestimated for diagnoses for which antibiotic use is not indicated, potentially leading to

downward bias in avertable exposures for these conditions. Additionally, NAMCS/NHAMCS

antibiotic use data does not include prescription details such as duration or dose. However, the

correlation between these factors and selection for resistance requires further study; prescriptions

may be a sufficient measure (Bruyndonckx et al., 2014; Lipsitch, 2001).

At the time of this analysis, Fleming-Dutra et al. remained the most up-to-date source of

unnecessary antibiotic prescribing by condition. Recent work with slightly different methods

found a lower proportion of inappropriate antibiotic prescriptions overall (23.2% compared to

30%) but did not report their estimates by condition (Chua et al., 2019). Although comparable

estimates of unnecessary prescribing over time are unavailable, multiple studies have shown that

declines in antibiotic use from approximately 2011 to 2016 in the United States have been

primarily due to pediatric prescribing, implying that, at least for adults, levels of unnecessary

prescribing likely remained similar (Durkin et al., 2018; King, Bartoces, Fleming-Dutra, Roberts,

& Hicks, 2019; Klevens et al., 2019; Olesen et al., 2018). Finally, we assume that the proportion

of unnecessary use is constant across antibiotics used for the same condition as it is difficult to

identify specific antibiotic prescriptions that were unwarranted without detailed chart review. A

study among outpatients in the Veterans Affairs medical system found that among prescriptions

for community-acquired pneumonia, sinusitis, and acute exacerbations of chronic bronchitis, the

highest proportion of macrolide use was inappropriate (27%), followed by penicillins (22%) and

quinolones (12%) (Tobia, Aspinall, Good, Fine, & Hanlon, 2008). Similar studies are needed to

understand which antibiotics are frequently used inappropriately for other indications and

settings.

Reductions in antibiotic consumption are necessary to preserve the potency of these drugs.

Quantifying changes in species-level exposures due to stewardship programs is one more step

towards understanding how changes in antibiotic use correspond to antibiotic resistance at the

population level. Further research, integrating knowledge from clinical, ecological, and

evolutionary spheres, is needed to elucidate this relationship (MacLean & San Millan, 2019).

The methods presented here may be easily extended to incorporate other data sources, such as

claims, or to assess more specific stewardship programs. We show that while improved

prescribing practices have the potential to prevent antibiotic exposures experienced by bacterial

species throughout the microbiome, complementary efforts to facilitate appropriate antibiotic

consumption and decrease overall infection incidence are required to substantially avert

exposures.

Acknowledgements
We thank Dr. Lauri Hicks for her helpful comments on this manuscript.
291
292   **Competing Interests**
293   ML has received consulting income from Affinivax, Antigen Discovery, Merck, and Pfizer and
294   research grants through Harvard School of Public Health from Pfizer and PATH. YHG has
295   received consulting income from Merck and GlaxoSmithKline. The authors have no other
296   relationships or activities that could appear to have influenced the submitted work.
297
Funding Sources
This work was supported by Grant U54GM088558 (Models of Infectious Disease Agent Study,
Center for Communicable Disease Dynamics) from the National Institute of General Medical
Sciences, Grant R01AI132606 from the National Institute of Allergy and Infectious Diseases (to
YHG), Grant CK000538-01 from the Centers for Disease Control and Prevention, and the Doris
Duke Charitable Foundation. CT is supported by Grant T32AI007535 from the National Institute
of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National Institute of General Medical
Sciences, National Institutes of Health, National Institute of Allergy and Infectious Diseases,
Centers for Disease Control and Prevention, Department of Health and Human Services, or the
Doris Duke Charitable Foundation.
309
310

311   **References**
312
Aitken, M., & Taylor, J. A. (1998). Prevalence of Clinical Sinusitis in Young Children Followed

Up by Primary Care Pediatricians. *Archives of Pediatrics & Adolescent Medicine*, *152*(3),

244–248. https://doi.org/10.1001/archpedi.152.3.244

Andersson, D. I., & Hughes, D. (2010). Antibiotic resistance and its cost: Is it possible to reverse

resistance? *Nature Reviews Microbiology*, *8*(4), 260–271.

https://doi.org/10.1038/nrmicro2319

Benninger, M. S., Holzer, S. E. S., & Lau, J. (2000). Diagnosis and treatment of uncomplicated

acute bacterial rhinosinusitis: Summary of the Agency for Health Care Policy and

Research evidence-based report. *Otolaryngology–Head and Neck Surgery*, *122*(1), 1–7.

https://doi.org/10.1016/S0194-5998(00)70135-5

Bluestone, C. D., Stephenson, J. S., & Martin, L. M. (1992). Ten-year review of otitis media

pathogens. *The Pediatric Infectious Disease Journal*, *11*(8), S7–S11.

https://doi.org/10.1097/00006454-199208001-00002

Brook, I. (2016). Microbiology of chronic rhinosinusitis. *European Journal of Clinical*

Microbiology & Infectious Diseases, *35*(7), 1059–1068. https://doi.org/10.1007/s10096-

016-2640-x

Bruyndonckx, R., Hens, N., Aerts, M., Goossens, H., Molenberghs, G., & Coenen, S. (2014).

Measuring trends of outpatient antibiotic use in Europe: Jointly modelling longitudinal

data in defined daily doses and packages. *Journal of Antimicrobial Chemotherapy*, *69*(7),

1981–1986. https://doi.org/10.1093/jac/dku063

Buffie, C. G., & Pamer, E. G. (2013). Microbiota-mediated colonization resistance against

intestinal pathogens. *Nature Reviews Immunology*, *13*(11), 790–801.

https://doi.org/10.1038/nri3535

Burgstaller, J. M., Steurer, J., Holzmann, D., Geiges, G., & Soyka, M. B. (2016). Antibiotic

efficacy in patients with a moderate probability of acute rhinosinusitis: A systematic

review. *European Archives of Oto-Rhino-Laryngology*, *273*(5), 1067–1077.

https://doi.org/10.1007/s00405-015-3506-z

Celin, S. E. (1991). Bacteriology of Acute Otitis Media in Adults. *JAMA*, *266*(16), 2249–2252.

https://doi.org/10.1001/jama.266.16.2249

Chua, K.-P., Fischer, M. A., & Linder, J. A. (2019). Appropriateness of outpatient antibiotic

prescribing among privately insured US patients: ICD-10-CM based cross sectional

study. *BMJ*, *364*(k5092). https://doi.org/10.1136/bmj.k5092

Durkin, M. J., Jafarzadeh, S. R., Hsueh, K., Sallah, Y. H., Munshi, K. D., Henderson, R. R., &

Fraser, V. J. (2018). Outpatient Antibiotic Prescription Trends in the United States: A

National Cohort Study. *Infection Control & Hospital Epidemiology*, *39*(5), 584–589.

https://doi.org/10.1017/ice.2018.26

European Centre for Disease Prevention and Control. (2018). *Antimicrobial consumption:*

Annual epidemiological report for 2017. Stockholm.

Filice, G. A., Drekonja, D. M., Thurn, J. R., Hamann, G. M., Masoud, B. T., & Johnson, J. R.

(2015). Diagnostic Errors that Lead to Inappropriate Antimicrobial Use. *Infection Control*

& Hospital Epidemiology, *36*(8), 949–956. https://doi.org/10.1017/ice.2015.113

Fleming-Dutra, K. E., Hersh, A. L., Shapiro, D. J., Bartoces, M., Enns, E. A., File, T. M., …

Hicks, L. A. (2016). Prevalence of Inappropriate Antibiotic Prescriptions Among US

Ambulatory Care Visits, 2010-2011. *JAMA*, *315*(17), 1864–1873.

https://doi.org/10.1001/jama.2016.4151

Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., … Soper, D. E.

(2011). International Clinical Practice Guidelines for the Treatment of Acute

Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious

Diseases Society of America and the European Society for Microbiology and Infectious

Diseases. *Clinical Infectious Diseases*, *52*(5), e103–e120.

https://doi.org/10.1093/cid/ciq257

Gupta, K., Scholes, D., & Stamm, W. E. (1999). Increasing prevalence of antimicrobial

resistance among uropathogens causing acute uncomplicated cystitis in women. *JAMA*,

281(8), 736–738. https://doi.org/10.1001/jama.281.8.736

Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J. H., Chinwalla, A. T., …

White, O. (2012). Structure, function and diversity of the healthy human microbiome.

Nature, *486*(7402), 207–214. https://doi.org/10.1038/nature11234

Kabbani, S., Hersh, A. L., Shapiro, D. J., Fleming-Dutra, K. E., Pavia, A. T., & Hicks, L. A.

(2018). Opportunities to Improve Fluoroquinolone Prescribing in the United States for

Adult Ambulatory Care Visits. *Clinical Infectious Diseases*, *67*(1), 134–136.

https://doi.org/10.1093/cid/ciy035

Khosravi, A., & Mazmanian, S. K. (2013). Disruption of the gut microbiome as a risk factor for

microbial infections. *Current Opinion in Microbiology*, *16*(2), 221–227.

https://doi.org/10.1016/j.mib.2013.03.009

King, L. M., Bartoces, M., Fleming-Dutra, K. E., Roberts, R. M., & Hicks, L. A. (2019).

Changes in US Outpatient Antibiotic Prescriptions from 2011-2016. *Clinical Infectious*

Diseases. https://doi.org/10.1093/cid/ciz225

Klevens, R. M., Caten, E., Olesen, S. W., DeMaria, A., Troppy, S., & Grad, Y. H. (2019).

Outpatient antibiotic prescribing in Massachusetts, 2011-2015. *Open Forum Infectious*

Diseases, *6*(5), ofz169. https://doi.org/10.1093/ofid/ofz169

Linder, J. A. (2008). *Editorial Commentary:* Antibiotics for Treatment of Acute Respiratory

Tract Infections: Decreasing Benefit, Increasing Risk, and the Irrelevance of

Antimicrobial Resistance. *Clinical Infectious Diseases*, *47*(6), 744–746.

https://doi.org/10.1086/591149

Lipsitch, M. (2001). The rise and fall of antimicrobial resistance. *Trends in Microbiology*, *9*(9),

438–444. https://doi.org/10.1016/S0966-842X(01)02130-8

MacLean, R. C., & San Millan, A. (2019). The evolution of antibiotic resistance. *Science*,

365(6458), 1082–1083. https://doi.org/10.1126/science.aax3879

Olesen, S. W., Barnett, M. L., MacFadden, D. R., Lipsitch, M., & Grad, Y. H. (2018). Trends in

outpatient antibiotic prescribing practice among US older adults, 2011-2015: An

observational study. *BMJ*, *362*, k3155. https://doi.org/10.1136/bmj.k3155

Public Health Agency of Canada. (2018). *Canadian Antimicrobial Resistance Surveillance*

System 2017 Report.

Public Health England. (2017). *English Surveillance Programme for Antimicrobial Utilisation*

and Resistance (ESPAUR) 2017.

Rosenfeld, R. M., Piccirillo, J. F., Chandrasekhar, S. S., Brook, I., Ashok Kumar, K., Kramper,

M., … Corrigan, M. D. (2015). Clinical Practice Guideline (Update): Adult Sinusitis.

Otolaryngology–Head and Neck Surgery, *152*(2_suppl), S1–S39.

https://doi.org/10.1177/0194599815572097

Sakoulas, G., Geriak, M., & Nizet, V. (2018). Is a Reported Penicillin Allergy Sufficient

Grounds to Forgo the Multidimensional Antimicrobial Benefits of β-Lactam Antibiotics?

Clinical Infectious Diseases, *68*, 157–164. https://doi.org/10.1093/cid/ciy557

Sande, M. A., & Gwaltney, J. M. (2004). Acute Community-Acquired Bacterial Sinusitis:

Continuing Challenges and Current Management. *Clinical Infectious Diseases*,

39(Supplement_3), S151–S158. https://doi.org/10.1086/421353

Shehab, N., Patel, P. R., Srinivasan, A., & Budnitz, D. S. (2008). Emergency Department Visits

for Antibiotic-Associated Adverse Events. *Clinical Infectious Diseases*, *47*(6), 735–743.

https://doi.org/10.1086/591126

Smith, S. S., Evans, C. T., Tan, B. K., Chandra, R. K., Smith, S. B., & Kern, R. C. (2013).

National burden of antibiotic use for adult rhinosinusitis. *Journal of Allergy and Clinical

Immunology*, *132*(5), 1230–1232. https://doi.org/10.1016/j.jaci.2013.07.009

Snow, V., Mottur-Pilson, C., Hickner, J. M., & for the American College of Physicians–

American Society of Internal Medicine*. (2001). Principles of Appropriate Antibiotic

Use for Acute Sinusitis in Adults. *Annals of Internal Medicine*, *134*(6), 495.

https://doi.org/10.7326/0003-4819-134-6-200103200-00016

Stewardson, A. J., Gaïa, N., François, P., Malhotra-Kumar, S., Delémont, C., Martinez de

Tejada, B., … Lazarevic, V. (2015). Collateral damage from oral ciprofloxacin versus

nitrofurantoin in outpatients with urinary tract infections: A culture-free analysis of gut

microbiota. *Clinical Microbiology and Infection*, *21*(4), 344.e1-344.e11.

https://doi.org/10.1016/j.cmi.2014.11.016

Swedres-Svarm. (2017). *Consumption of antibiotics and occurrence of antibiotic resistance in*

Sweden. Public Health Agency of Sweden and National Veterinary Institute.

Tedijanto, C., Olesen, S. W., Grad, Y. H., & Lipsitch, M. (2018). Estimating the proportion of

bystander selection for antibiotic resistance among potentially pathogenic bacterial flora.

Proceedings of the National Academy of Sciences, *115*(51), E11988–E11995.

https://doi.org/10.1073/pnas.1810840115

The Human Microbiome Project Consortium. (2012). A framework for human microbiome

research. *Nature*, *486*(7402), 215–221. https://doi.org/10.1038/nature11209

Tobia, C., Aspinall, S., Good, C., Fine, M., & Hanlon, J. (2008). Appropriateness of antibiotic

prescribing in veterans with community-acquired pneumonia, sinusitis, or acute

exacerbations of chronic bronchitis: A cross-sectional study. *Clinical Therapeutics*,

30(6), 1135–1144. https://doi.org/10.1016/j.clinthera.2008.06.009

Tomas, M. E., Getman, D., Donskey, C. J., & Hecker, M. T. (2015). Overdiagnosis of Urinary

Tract Infection and Underdiagnosis of Sexually Transmitted Infection in Adult Women

Presenting to an Emergency Department. *Journal of Clinical Microbiology*, *53*(8), 2686–

2692. https://doi.org/10.1128/JCM.00670-15

Vanden Eng, J., Marcus, R., Hadler, J. L., Imhoff, B., Vugia, D. J., Cieslak, P. R., … Besser, R.

E. (2003). Consumer Attitudes and Use of Antibiotics. *Emerging Infectious Diseases*,

9(9), 1128–1135. https://doi.org/10.3201/eid0909.020591

Wald, E. R., Guerra, N., & Byers, C. (1991). Upper Respiratory Tract Infections in Young

Children: Duration of and Frequency of Complications. *Pediatrics*, *87*(2), 129–133.

444 Williams, J. W., Simel, D. L., Roberts, L., & Samsa, G. P. (1992). Clinical Evaluation for

445   Sinusitis. *Annals of Internal Medicine*, *117*(9), 705–710. https://doi.org/10.7326/0003-

446   4819-117-9-705

449 **Supplementary Materials**
450
451 **Title:** Potential impact of outpatient stewardship interventions on antibiotic exposures of
452 bacterial pathogens
453
454 **Authors:** Christine Tedijanto, Yonatan H. Grad, Marc Lipsitch
455
456 **Appendix Table 1.** Notation, descriptions, and sources for variables in Equation 1.
457
458 **Appendix Table 2.** Modifications to proportions of unnecessary antibiotic prescriptions based
459 on published etiology studies. Modifications were made if the reported proportion of bacterial
460 cases for a given condition exceeded the estimated proportion of appropriate prescriptions
461 reported in Fleming-Dutra et al.
462
463 **Appendix Figure 1.** Sensitivity analysis of proportions of avertable exposures across all
464 outpatient conditions when proportion of unnecessary use is applied equally across target and
465 bystander exposures.
466
467 **Appendix Figure 2.** Proportion of avertable exposures when all unnecessary use for outpatient
468 conditions is eliminated against proportion of bystander exposures.
469
470 **Appendix Figure 3.** Sensitivity analysis for Scenario 3 (elimination of all antibiotic use for
471 acute sinusitis).
472
473 **Appendix Figure 4.** Proportions of avertable exposures using 2010-2011 NAMCS/NHAMCS
474 data with and without NHAMCS outpatient department data.
475

476 **Appendix Table 1.** Notation, descriptions, and sources for variables in Equation 1.

Variable	Definition	Source
d_{aig}	Number of prescriptions (using nationally representative weights) of antibiotic a associated with ICD9-CM diagnosis code i in age group g	NAMCS/NHAMCS 2015
e_{sig}	Proportion of cases of condition defined by ICD9-CM diagnosis code i in age group g caused by species s	Published etiology studies
p_{s0g}	Asymptomatic carriage prevalence of species s in age group g	Human Microbiome Project (HMP) and published carriage studies
p_{sig}	Carriage prevalence of species s among individuals diagnosed with ICD9-CM code i in age group g	$e_{sig} + (1 - e_{sig})p_{s0g}$
q_{aig}	Proportion of prescriptions of antibiotic a associated with ICD9-CM diagnosis code i in age group g that are avertable under the given scenario	Fleming-Dutra et al. 2016 (Fleming-Dutra et al., 2016); note that this variable is only dependent on a in the nitrofurantoin-specific scenario
X_{as}	Number of exposures of antibiotic a experienced by species s that are avertable under the given scenario	$\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig} \times q_{aig}$
T_{as}	Total number of exposures of antibiotic a experienced by species s	$\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig}$

477
478

479 **Appendix Table 2.** Modifications to proportions of unnecessary antibiotic prescriptions based
480 on published etiology studies and antibiotic use in NAMCS/NHAMCS. Modifications were
481 made if the reported proportion of bacterial cases for a given condition exceeded the estimated
482 proportion of appropriate prescriptions reported in Fleming-Dutra et al. (Fleming-Dutra et al.,
483 2016)

Age group	Fleming-Dutra estimate	New estimate	Explanation
Pharyngitis			
0-19 years old	34%	Pharyngitis: 48%; Strep throat: 0%	Assuming that all strep-associated use of our antibiotics of interest (based on NAMCS/NHAMCS) was necessary, we estimated the proportion of non-strep pharyngitis antibiotic use that would have to be eliminated to maintain the overall estimate reported by Fleming-Dutra et al. (Fleming-Dutra et al., 2016)
20-64 years old	75%	Updated to 58% overall; Pharyngitis: 100%; Strep throat: 0%	
>64 years old	NA (assume 0%)	NA (assume 0%)	No change.
Sinusitis			
0-19 years old	9%	Acute: 16%; Chronic: 0%	While acute sinusitis is rarely bacterial, bacteria are believed to play a much more prominent role in the etiology of chronic sinusitis (Brook, 2016). Thus, we assume that antibiotic use would only be eliminated from acute sinusitis and maintain the overall estimate of unnecessary use reported by Fleming-Dutra et al. (Fleming-Dutra et al., 2016) when possible.
20-64 years old	51%	Updated to 40% overall; Acute: 100%; Chronic: 0%	
>64 years old	16%	Acute: 34%; Chronic: 0%	
Suppurative otitis media			
0-19 years old	10%	10%	No change. Approximately 84% of pediatric cases were found to have bacterial growth (Bluestone, Stephenson, & Martin, 1992), so 10% is a reasonable estimate for avertable use.
20-64 years old	33%	26%	Based on an etiology study in adults, only 26% of cases were found to have no bacterial growth (Celin, 1991).
>64 years old	NA (assume 0%)	NA (assume 0%)	No change.

484
485

486 **Appendix Figure 1.** Sensitivity analysis of proportions of avertable exposures across all
487 outpatient conditions when proportion of unnecessary use is applied equally across target and
488 bystander exposures (Equation 1 without modification).
489

490
491
Abbreviations: *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,
AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,
CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,
TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin;
Organisms (x-axis): EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*,
SA=*S. aureus*, SAg=*S. agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years
498

499 **Appendix Figure 2.** Proportion of avertable exposures when all unnecessary use for outpatient
500 conditions is eliminated against proportion of bystander exposures (Tedijanto et al., 2018).
501

502
503
504

Appendix Figure 3. Sensitivity analysis for Scenario 3 (elimination of all antibiotic use for
acute sinusitis).

A. Use estimates of bacterial etiology to approximate appropriate antibiotic use for acute
sinusitis. The following upper bound estimates for the proportion of acute sinusitis cases with
bacterial etiology were used: 2% for adults and 13% for children (applied to 0-19 year old age
group) (Sande & Gwaltney, 2004; Snow, Mottur-Pilson, Hickner, & for the American College of
Physicians–American Society of Internal Medicine*, 2001; Wald, Guerra, & Byers, 1991).

B. Use estimates of bacterial etiology among those presenting to primary care clinics.
Patients visiting the clinic are likely to have more persistent, severe, or worsening symptoms,
which may be indications of bacterial etiology. Studies have estimated that approximately 38%
of adults and 17% of children (upper bounds) visiting primary care for symptoms of acute upper
respiratory tract infection have bacterial rhinosinusitis (Aitken & Taylor, 1998; Benninger,
Holzer, & Lau, 2000; Williams, Simel, Roberts, & Samsa, 1992).

Abbreviations: *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,
AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,
CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,
TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin; *Organisms (x-axis):*
EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAg=*S. agalactiae*,
SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years

Appendix Figure 4. Proportions of avertable exposures using 2010-2011 NAMCS/NHAMCS
data with *(left)* and without *(right)* NHAMCS outpatient department data.

A. Eliminate unnecessary antibiotic use across all outpatient conditions.

B. Eliminate all antibiotic use for outpatient respiratory conditions for which antibiotics
are not indicated.

C. Eliminate all antibiotic use for acute sinusitis.

D. Prescribe nitrofurantoin for all cases of cystitis in women.

539
Abbreviations: *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,
AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,
CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,
TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin; *Organisms (x-axis):*
EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAg=*S. agalactiae*,
SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years